Author(s):
Kote Rupali Balasaheb, Jinat Maniyar, Jadhav Ravindra S, Mule Asmita, Khetmalis Aditya, Monika Magar, Nikita Borse
Email(s):
rupalikote236@gmail.com
DOI:
10.52711/2321-5836.2026.00010 
Address:
Kote Rupali Balasaheb, Jinat Maniyar*, Jadhav Ravindra S, Mule Asmita, Khetmalis Aditya, Monika Magar, Nikita Borse
Department of Pharmaceutics, Pravara Rural Education Society's Institute of Pharmacy, Loni, MS, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 1,
Year - 2026
ABSTRACT:
Topical drug delivery systems (TDDS) have evolved significantly over the past several decades, offering targeted and localized therapy through the skin while minimizing systemic exposure. The skin, as the largest organ and a complex barrier, provides both accessibility and selectivity for drug administration. Conventional topical formulations, including ointments, creams, gels, and lotions, have proven effective for certain dermatological conditions; however, they often face limitations related to drug penetration, bioavailability, stability, and patient compliance. Advances in pharmaceutical technology have led to innovative delivery strategies such as nano-based carriers, liposomes, ethosomes, niosomes, transferosomes, solid lipid nanoparticles, and microneedle systems, which enhance therapeutic efficacy and overcome limitations of traditional formulations. TDDS also leverages physical and chemical enhancement methods, including sonophoresis, electroporation, iontophoresis, and chemical penetration enhancers, to improve drug permeation and retention. Future perspectives emphasize the integration of transdermal patches, hybrid chemical-physical approaches, and optimized formulation design to ensure stability, targeted delivery, and minimal side effects. The transition from conventional to carrier-mediated and advanced topical systems represents a promising avenue for effective treatment of localized and systemic conditions, including hydrophilic and macromolecular drugs, thereby improving patient adherence and overall therapeutic outcomes.
Cite this article:
Kote Rupali Balasaheb, Jinat Maniyar, Jadhav Ravindra S, Mule Asmita, Khetmalis Aditya, Monika Magar, Nikita Borse. Topical Drug Delivery System. Research Journal of Pharmacology and Pharmacodynamics. 2026;18(1):81-6. doi: 10.52711/2321-5836.2026.00010
Cite(Electronic):
Kote Rupali Balasaheb, Jinat Maniyar, Jadhav Ravindra S, Mule Asmita, Khetmalis Aditya, Monika Magar, Nikita Borse. Topical Drug Delivery System. Research Journal of Pharmacology and Pharmacodynamics. 2026;18(1):81-6. doi: 10.52711/2321-5836.2026.00010 Available on: https://rjppd.org/AbstractView.aspx?PID=2026-18-1-10
REFERENCES:
1. Surver C, Davis FA. Bioavailability and bioequivalence. Dermatological and Transdermal Formulation. Marcal Dekker Inc, New York. 2002; 119:403–23.
2. Tadwee IK, Gore S, Giradkar P. Advances in topical drug delivery system: a review. Int J Pharm Res Allied Sci. 2012; 1(1):14–23.
3. Das Kurmi B, Tekchandani P, Paliwal R, Rai Paliwal S. Transdermal drug delivery: opportunities and challenges for controlled delivery of therapeutic agents using nanocarriers. Curr Drug Metab. 2017; 18(5): 481–95.
4. Shinde GS, Jadhav R, Vikhe D, Kote RB. Development and evaluation of herbal fast disintegrating tablet of Achyranthes aspera linn root extract. Asian J Pharm Technol. 2024; 14(2): 119–22.
5. Date AA, Naik B, Nagarsenker MS. Novel drug delivery systems: potential in improving topical delivery of antiacne agents. Skin Pharmacol Physiol. 2005; 19(1):2–16.
6. Singh Malik D, Mital N, Kaur G. Topical drug delivery systems: a patent review. Expert Opin Ther Pat. 2016; 26(2): 213–28.
7. Kale VR. Topical preparation: past, present and future perspective – a review. 2019;6(5):10094–10110.
8. Kumar D, Sharma N, Rana AC, Agarwal G, Bhat ZA. A review: transdermal drug delivery system: a tools for novel drug delivery system. Int J Drug Dev Res. 2011; 3(3): 70–84.
9. Bangarwa S, Garg S, Aseri A. A review on antifungal gels: as a topical drug delivery system. Int J Pharm Technol Biotechnol. 2014; 1:48–55.
10. Hmingthansanga V, Singh N, Banerjee S, Manickam S, Velayutham R, Natesan S. Improved topical drug delivery: role of permeation enhancers and advanced approaches. Pharmaceutics. 2022; 14(12): 2818.
11. Roberts MS, Cross SE. Percutaneous absorption of topically applied NSAIDs and other compounds: role of solute properties, skin physiology and delivery systems. Inflammopharmacology. 1999; 7: 339–50.
12. Moser K, Kriwet K, Naik A, Kalia YN, Guy RH. Passive skin penetration enhancement and its quantification in vitro. Eur J Pharm Biopharm. 2001;52(2):103–12.
13. Rolland A, Brzokewicz A, Shroot B, Jamoulle JC. Effect of penetration enhancers on the phase transition of multilamellar liposomes of dipalmitoylphosphatidylcholine: a study by differential scanning calorimetry. Int J Pharm. 1991;76(3):217–24.
14. Desai P, Patlolla RR, Singh M. Interaction of nanoparticles and cell-penetrating peptides with skin for transdermal drug delivery. Mol Membr Biol. 2010;27(7):247–59.
15. Shinde G, Godage RK, Jadhav RS, Manoj B, Aniket B. A Review on Advances in UV Spectroscopy. Res J Sci Technol. 2020;12(1):47–51.
16. Godge RK, Shinde GS, Joshi S. Simultaneous Estimation and Validation of Dapagliflozin and Saxagliptin in Bulk Drug and Dosage Form by RP-HPLC. Res J Sci Technol. 2019; 11(1):59–63.
17. Malan SF, Chetty DJ, Du Plessis J. Physicochemical properties of drugs and membrane permeability. S Afr J Sci. 2002; 98(7): 385–91.
18. Bolzinger MA, Briançon S, Pelletier J, Chevalier Y. Penetration of drugs through skin, a complex rate-controlling membrane. Curr Opin Colloid Interface Sci. 2012;17(3):156–65.
19. Supe S, Takudage P. Methods for evaluating penetration of drug into the skin: a review. Skin Res Technol. 2021; 27(3): 299–308.
20. Shinde GS, Jadhav RS, Kote RB, Kadam AJ, Bankar AA. Bioanalytical Method Development and Validation of UV Spectrophotometric Method for Estimation of Metformin Hydrochloride in Urine Sample. Asian J Res Chem. 2024;17(2):93–6.
21. Shinde GS, Jadhav RS, Tambe VB, Kote RB. RP-HPLC Method Development and Validation of Lamivudine, Zidovudine and Nevirapine in Bulk and Dosage Form using UV Detector. Res J Pharm Technol. 2024;17(10):5011–5.
22. Lademann J, Richter H, Schanzer S, Knorr F, Meinke M, Sterry W, Patzelt A. Penetration and storage of particles in human skin: perspectives and safety aspects. Eur J Pharm Biopharm. 2011;77(3):465–8.
23. Monteiro-Riviere NA. Structure and function of skin. Toxicol Skin. 2010;1.
24. Chuong CM, Nickoloff BJ, Elias PM, Goldsmith LA, Macher E, Maderson PA, Christophers E. What is the 'true' function of skin? Exp Dermatol. 2002;11(2):159–87.
25. Swadghane R, Bhor R, Shinde G. A review on some biological activities of Hyantion Derivative. 2023;13(1):173–8.
26. Hardenia A, Jayronia S, Jain S. Emulgel: an emergent tool in topical drug delivery. Int J Pharm Sci Res. 2014;5(5):1653.
27. Mishra A, Panola R, Vyas B, Marothia D, Kansara H. Topical antibiotics and semisolid dosage forms. Int J Pharm Erud. 2014; 4:33–54.
28. Singh Malik D, Mital N, Kaur G. Topical drug delivery systems: a patent review. Expert Opin Ther Pat. 2016;26(2):213–28.
29. Sharadha M, Gowda DV, Vishal Gupta N, Akhila AR. An overview on topical drug delivery system – updated review. Int J Res Pharm Sci. 2020;11(1):368–85.
30. Shah VP, Yacobi A, Radulescu F, Miron DS, Lane ME. A science-based approach to topical drug classification system (TCS). Int J Pharm. 2015;491(1–2):21–5.
31. Sultana SS, Parveen P, Rekha MS, Deepthi K, Sowjanya CH, Devi AS. Emulgel – a novel surrogate approach for transdermal drug delivery system. Ind Am J Pharm Res. 2014; 4:5250–65.
32. Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000;9(3):165–9.
33. Raina N, Rani R, Thakur VK, Gupta M. New insights in topical drug delivery for skin disorders: from a nanotechnological perspective. ACS Omega. 2023.
34. Benson HA, Grice JE, Mohammed Y, Namjoshi S, Roberts MS. Topical and transdermal drug delivery: from simple potions to smart technologies. Curr Drug Deliv. 2019;16(5):444–60.
35. Moghimi HR, Shafizade A, Kamlinejad M. Drug delivery systems in Iranian traditional pharmacy. Tradit Med Mater Med Res Cent SBMU Tehran Iran. 2011.
36. Lin TJ. Evolution of cosmetics: increased need for experimental clinical medicine. J Exp Clin Med. 2010;2(2):49–52.
37. Chien YW. Development of transdermal drug delivery systems. Drug Dev Ind Pharm. 1987;13(4–5):589–651.
38. Brown AM, Kaplan LM, Brown ME. Phenol-induced histological skin changes: hazards, technique, and uses. Br J Plast Surg. 1960; 13:158–69.
39. Roberts MS, Cheruvu HS, Mangion SE, Alinaghi A, Benson HA, Mohammed Y, Grice JE. Topical drug delivery: history, percutaneous absorption, and product development. Adv Drug Deliv Rev. 2021; 177:113929.
40. Zondek B. The excretion of halogenized phenols and their use in the treatment of urogenital infections: percutaneous chemotherapy. J Urol. 1942;48(6):747–58.
41. Lund F. Percutaneous nitroglycerin treatment in cases of peripheral circulatory disorders, especially Raynaud's disease. Acta Med Scand. 1948;130(S206):196–206.
42. Higuchi T. Physical chemical analysis of percutaneous absorption process from creams and ointments. J Soc Cosmet Chem. 1960; 11:85–97.
43. Roberts MS, Anderson RA, Swarbrick J. Permeability of human epidermis to phenolic compounds. J Pharm Pharmacol. 1977;29(1):677–83.
44. Katz M, Poulsen BJ. Absorption of drugs through the skin. In: Concepts in Biochemical Pharmacology: Part 1. Springer, Berlin, Heidelberg. 1971;103–74.
45. Roberts MS, Anderson RA, Swarbrick J, Moore DE. The percutaneous absorption of phenolic compounds: the mechanism of diffusion across the stratum corneum. J Pharm Pharmacol. 1978;30(1):486–90.
46. Pastore MN, Kalia YN, Horstmann M, Roberts MS. Transdermal patches: history, development and pharmacology. Br J Pharmacol. 2015;172(9):2179–209